Form 8-K - Current report:
SEC Accession No. 0001104659-25-004007
Filing Date
2025-01-16
Accepted
2025-01-16 11:56:32
Documents
16
Period of Report
2025-01-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm253514d1_8k.htm   iXBRL 8-K 33068
2 EXHIBIT 4.1 tm253514d1_ex4-1.htm EX-4.1 102820
3 EXHIBIT 4.2 tm253514d1_ex4-2.htm EX-4.2 99261
4 EXHIBIT 10.1 tm253514d1_ex10-1.htm EX-10.1 60712
  Complete submission text file 0001104659-25-004007.txt   544026

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA eyen-20250116.xsd EX-101.SCH 3015
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE eyen-20250116_lab.xml EX-101.LAB 34240
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eyen-20250116_pre.xml EX-101.PRE 22359
18 EXTRACTED XBRL INSTANCE DOCUMENT tm253514d1_8k_htm.xml XML 3676
Mailing Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017
Business Address 295 MADISON AVENUE, SUITE 2400 NEW YORK NY 10017 813-766-9539
EYENOVIA, INC. (Filer) CIK: 0001682639 (see all company filings)

EIN.: 471178401 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38365 | Film No.: 25534885
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)